FDA committee to discuss fixed-combo CV drugs

FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on Sept. 10 to discuss the clinical utility of a fixed-combination product comprising an anti-hypertensive drug, aspirin and a statin ...